» Articles » PMID: 17579092

Inhibited Aortic Aneurysm Formation in BLT1-deficient Mice

Overview
Journal J Immunol
Date 2007 Jun 21
PMID 17579092
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Leukotriene B(4) is a proinflammatory lipid mediator generated by the enzymes 5-lipoxygenase and leukotriene A(4) hydrolase. Leukotriene B(4) signals primarily through its high-affinity G protein-coupled receptor, BLT1, which is highly expressed on specific leukocyte subsets. Recent genetic studies in humans as well as knockout studies in mice have implicated the leukotriene synthesis pathway in several vascular pathologies. In this study, we tested the hypothesis that BLT1 is necessary for abdominal aortic aneurysm (AAA) formation, a major complication of atherosclerotic vascular disease. Chow-fed Apoe(-/-) and Apoe(-/-)/Blt1(-/-) mice were treated with a 4-wk infusion of angiotensin II (1000 ng/min/kg) beginning at 20 wk of age, in a well-established murine AAA model. We found a reduced incidence of AAA formation as well as concordant reductions in the maximum suprarenal/infrarenal diameter and total suprarenal/infrarenal area in the angiotensin II-treated Apoe(-/-)/Blt1(-/-) mice as compared with the Apoe(-/-) controls. Diminished AAA formation in BLT1-deficient mice was associated with significant reductions in mononuclear cell chemoattractants and leukocyte accumulation in the vessel wall, as well as striking reductions in the production of matrix metalloproteinases-2 and -9. Thus, we have shown that BLT1 contributes to the frequency and size of abdominal aortic aneurysms in mice and that BLT1 deletion in turn inhibits proinflammatory circuits and enzymes that modulate vessel wall integrity. These findings extend the role of BLT1 to a critical complication of vascular disease and underscore its potential as a target for intervention in modulating multiple pathologies related to atherosclerosis.

Citing Articles

[Establishment and Validation of an Animal Model of Abdominal Aortic Aneurysm in Beagles Through Vascular Patch Angioplasty and Elastase Infusion].

Ge J, Zhu C, Weng C, Yuan D Sichuan Da Xue Xue Bao Yi Xue Ban. 2024; 54(6):1276-1282.

PMID: 38162059 PMC: 10752763. DOI: 10.12182/20231160205.


Advanced Research of Abdominal Aortic Aneurysms on Metabolism.

Hou Y, Guo W, Fan T, Li B, Ge W, Gao R Front Cardiovasc Med. 2021; 8:630269.

PMID: 33614752 PMC: 7892590. DOI: 10.3389/fcvm.2021.630269.


Complement Factor C5a Is Increased in Blood of Patients with Abdominal Aortic Aneurysm and Has Prognostic Potential for Aneurysm Growth.

Zagrapan B, Eilenberg W, Scheuba A, Klopf J, Brandau A, Story J J Cardiovasc Transl Res. 2020; 14(4):761-769.

PMID: 33332020 PMC: 8397625. DOI: 10.1007/s12265-020-10086-5.


Pharmacologic Management of Aneurysms.

Lindeman J, Matsumura J Circ Res. 2019; 124(4):631-646.

PMID: 30763216 PMC: 6386187. DOI: 10.1161/CIRCRESAHA.118.312439.


Resolution of Inflammation Through the Lipoxin and ALX/FPR2 Receptor Pathway Protects Against Abdominal Aortic Aneurysms.

Petri M, Thul S, Andonova T, Lindquist-Liljeqvist M, Jin H, Skenteris N JACC Basic Transl Sci. 2019; 3(6):719-727.

PMID: 30623131 PMC: 6314955. DOI: 10.1016/j.jacbts.2018.08.005.